Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[External validation of the ETVSS scale for predicting the outcomes after third ventriculostomy in children less than one year of age with obstructive hydrocephalus].

Zhurnal voprosy neirokhirurgii imeni N. N. Burdenko·2025
Same author

Consumer Trend of Using Ready-to-Use Salted Napa Cabbage at Home: Current Consumer Behaviors, Beliefs, and Opinions about the Main Ingredient of Kimchi.

Journal of food protection·2022
Same author

Relooking the monkeypox virus during this present outbreak: epidemiology to therapeutics and vaccines.

European review for medical and pharmacological sciences·2022
Same author

Evaluate the safety and efficacy of dura sealant patch in reducing cerebrospinal fluid leakage following elective cranial surgery (ENCASE II): study protocol for a randomized, two-arm, multicenter trial.

Trials·2022
Same author

[Cranial suture ultrasound for reducing radiation exposure in diagnosis of craniosynostosis in young children].

Zhurnal voprosy neirokhirurgii imeni N. N. Burdenko·2022
Same author

COVID-19 vaccines and vaccination program for aging adults.

European review for medical and pharmacological sciences·2021

Related Experiment Video

Updated: Jun 20, 2026

The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice

Published on: November 1, 2015

IAN5 polymorphisms are associated with systemic lupus erythematosus.

M K Lim1, D H Sheen, S A Kim

  • 1Department of Medicine, School of Medicine and Medical Sciences Research Institute, Eulji University, 302-799 Daejeon, South Korea.

Lupus
|September 19, 2009
PubMed
Summary

Investigating the immune-associated nucleotide 5 (IAN5) gene in a Korean population revealed specific single nucleotide polymorphisms (SNPs) linked to systemic lupus erythematosus (SLE) susceptibility and disease characteristics.

More Related Videos

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
07:26

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

Related Experiment Videos

Last Updated: Jun 20, 2026

The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice

Published on: November 1, 2015

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
07:26

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

Area of Science:

  • Genetics
  • Immunology
  • Rheumatology

Background:

  • Systemic lupus erythematosus (SLE) is an autoimmune disease often accompanied by lymphopenia.
  • The Biobreeding (BB) rat model exhibits autoimmune disease and lymphopenia due to a mutation in the immune-associated nucleotide 5 (IAN5) gene.
  • The IAN5 gene plays a role in T-cell activation and survival.

Purpose of the Study:

  • To investigate the association between single nucleotide polymorphisms (SNPs) in the IAN5 gene and systemic lupus erythematosus (SLE).
  • To explore the relationship between IAN5 gene variations and clinical manifestations of SLE in a Korean population.

Main Methods:

  • A case-control study was conducted involving 132 SLE patients, 505 rheumatoid arthritis patients, and 546 controls.
  • Genotyping was performed for four specific SNPs within the IAN5 gene.
  • Haplotype analysis was utilized to examine combinations of SNPs.

Main Results:

  • Two IAN5 SNPs (+2071C > T and +2677G > A) were significantly associated with SLE susceptibility (P = 0.040 and 0.045).
  • The -4432G > A SNP correlated with leukopenia and the need for steroid pulse therapy in SLE patients (P = 0.028 and 0.040).
  • Specific haplotypes (Ht1, Ht4, Ht5, Ht6) were linked to SLE susceptibility and nephritis development.

Conclusions:

  • IAN5 gene polymorphisms are associated with susceptibility to systemic lupus erythematosus (SLE).
  • Specific IAN5 variations correlate with the development of clinical disease manifestations, including leukopenia and nephritis.
  • These findings highlight the role of IAN5 in SLE pathogenesis within the studied Korean population.